Search

Your search keyword '"Belani C"' showing total 357 results
Start Over Author "Belani C"
357 results on '"Belani C"'

1. EP08.01-060 Long term Survival Outcomes in NSCLC Patients with Targeted Therapy and Immunotherapy: An IASLC Analysis of ASCO CancerLinQ Discovery Data

Author

Behera, M., primary, Joseph, G., additional, Rupji, M., additional, Huang, Z., additional, Bunn, B., additional, Wynes, M., additional, Switchenko, J., additional, Scagliotti, G., additional, Higgins, K., additional, Tsao, M., additional, Belani, C., additional, Sequist, L., additional, and Ramalingam, S.S., additional

Published
2022
Full Text
View/download PDF

14. Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC

Author

Ardizzoni, A, Tiseo, M, Boni, L, Di Maio, M, Buffoni, L, Belvedere, O, Grossi, F, D'Alessandro, V, de Marinis, F, Barbera, S, Caroti, C, Favaretto, A, Cortinovis, D, Morrica, B, Tixi, L, Ceschia, T, Parisi, S, Ricardi, U, Grimaldi, A, Loreggian, L, Navarria, P, Huber, R, Belani, C, Bruswig, P, Scagliotti, G, Scolaro, T, Ardizzoni A, Tiseo M, Boni L, Di Maio M, Buffoni L, Belvedere O, Grossi F, D'Alessandro V, de Marinis F, Barbera S, Caroti C, Favaretto A, Cortinovis D, Morrica B, Tixi L, Ceschia T, Parisi S, Ricardi U, Grimaldi A, Loreggian L, Navarria P, Huber RM, Belani C, Bruswig PF, Scagliotti GV, Scolaro T., Ardizzoni, A, Tiseo, M, Boni, L, Di Maio, M, Buffoni, L, Belvedere, O, Grossi, F, D'Alessandro, V, de Marinis, F, Barbera, S, Caroti, C, Favaretto, A, Cortinovis, D, Morrica, B, Tixi, L, Ceschia, T, Parisi, S, Ricardi, U, Grimaldi, A, Loreggian, L, Navarria, P, Huber, R, Belani, C, Bruswig, P, Scagliotti, G, Scolaro, T, Ardizzoni A, Tiseo M, Boni L, Di Maio M, Buffoni L, Belvedere O, Grossi F, D'Alessandro V, de Marinis F, Barbera S, Caroti C, Favaretto A, Cortinovis D, Morrica B, Tixi L, Ceschia T, Parisi S, Ricardi U, Grimaldi A, Loreggian L, Navarria P, Huber RM, Belani C, Bruswig PF, Scagliotti GV, and Scolaro T.

Abstract

Background Chemo-radiotherapy is standard of care in the treatment of unresectable stage III NSCLC. We aimed at assessing whether the addition of concurrent taxane-chemotherapy to thoracic irradiation following chemotherapy was able to improve treatment outcome. Material and methods In PITCAP trial, patients with unresectable stage III NSCLC were randomized to receive 2 cycles of platinum-paclitaxel followed by 60–61.2 Gy thoracic irradiation (control arm) or by same radiotherapy with concomitant weekly paclitaxel (experimental arm). A literature-based meta-analysis including all studies with same design was also performed. Results At the time of the second interim analysis, when 151 patients were randomized, accrual was terminated. With a median follow-up of 6.1 years, median survival was 13.2 vs 15.1 months, with a 3-year survival rate of 19.5 vs 21.2% in the control and experimental arm, respectively (HR: 0.97; 95% CI 0.69–1.36; p = 0.845). Treatment toxicity was manageable in both arms. The meta-analysis of 5 trials (n = 866) confirmed the lack of a meaningful effect on 1-year overall survival of a taxane added concurrently to radiotherapy. Conclusions These results do not support a meaningful survival benefit with the addition of single agent taxane given concurrently to radiotherapy after platinum-based induction in locally advanced NSCLC.

Published
2016

17. P3.16-45 The Rates and Survival of Surgically-Resected Second Primary Lung Cancers in Patients Undergoing Resection of an Initial Primary Lung Cancer.

Author

Varlotto, J., primary, Voland, R., additional, Mckie, K., additional, Decamp, M., additional, Maddox, D., additional, Rava, P., additional, Fitzgerald, T., additional, Uy, K., additional, Toth, J., additional, Oliveira, P., additional, Reed, M., additional, Belani, C., additional, Baima, J., additional, Zhang, J., additional, Walsh, W., additional, Patel, M., additional, Rosen, M., additional, Mcintosh, L., additional, Rassaei, N., additional, and Flickinger, J., additional

Published
2018
Full Text
View/download PDF

18. MA23.05 Post-Operative Radiation Improves Overall Survival in Patients with Node-Positive Non-Small Cell Lung Cancer Undergoing Sublobar Resections

Author

Uy, K.F., primary, Voland, R., additional, Varlotto, J., additional, Decamp, M., additional, Mckie, K., additional, Maddox, D., additional, Rava, P., additional, Fitzgerald, T., additional, Toth, J., additional, Oliveira, P., additional, Reed, M., additional, Belani, C., additional, Baima, J., additional, Zhang, J., additional, Walsh, W., additional, Patel, M., additional, Rosen, M., additional, Mcintosh, L., additional, Rassaei, N., additional, and Flickinger, J., additional

Published
2018
Full Text
View/download PDF

19. MA 13.08 Long Term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): a Randomized Phase II Study of 2 SBRT Schedules for Lung Cancer

Author

Videtic, G., primary, Paulus, R., additional, Singh, A., additional, Chang, J., additional, Parker, W., additional, Olivier, K., additional, Timmerman, R., additional, Komaki, R., additional, Urbanic, J., additional, Stephans, K., additional, Yom, S., additional, Robinson, C., additional, Belani, C., additional, Iyengar, P., additional, Ajlouni, M., additional, Gopaul, D., additional, Lele, S., additional, Mcgarry, R., additional, Choy, H., additional, and Bradley, J., additional

Published
2017
Full Text
View/download PDF

21. Long-Term Follow-Up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients with Stage I Peripheral Non–small Cell Lung Cancer

Author

Videtic, G.M., primary, Paulus, R., additional, Singh, A.K., additional, Chang, J.Y., additional, Parker, W., additional, Olivier, K., additional, Timmerman, R.D., additional, Komaki, R.U., additional, Urbanic, J.J., additional, Stephans, K.L., additional, Yom, S.S., additional, Robinson, C.G., additional, Belani, C., additional, Iyengar, P., additional, Ajlouni, M., additional, Gopaul, D.D., additional, Lele, S., additional, McGarry, R.C., additional, Choy, H., additional, and Bradley, J.D., additional

Published
2017
Full Text
View/download PDF

22. Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patients

Author

Ramaekers, B. L., Joore, M. A., Lueza, B., Bonastre, J., Mauguen, A., Pignon, J. P., Le Pechoux, C., Ruysscher, D. K., Grutters, J. P., Arriagada, R., Bae, K., Ball, D., Baumann, M., Behrendt, K., Belani, C. P., Beresford, J., Bishop, J., Bonner, J. A., Choy, H., Dahlberg, S. E., and (MAR-LC Collaborative group)

Subjects
Radiotherapy, Markov chain, Cost-benefit analysis, Dose fractionation, Non-small-cell lung cancer
Abstract

Introduction: Modified fractionation radiotherapy (RT), delivering multiple fractions per day or shortening the overall treatment time, improves overall survival for non-small-cell lung cancer (NSCLC) patients compared with conventional fractionation RT (CRT). However, its cost effectiveness is unknown. Therefore, we aimed to examine and compare the cost effectiveness of different modified RT schemes and CRT in the curative treatment of unresected NSCLC patients. Methods: A probabilistic Markov model was developed based on individual patient data from the meta-analysis of radiotherapy in lung cancer (N = 2000). Dutch health care costs, quality-adjusted life years (QALYs), and net monetary benefits (NMBs) were compared between two accelerated schemes (very accelerated RT [VART] and moderately accelerated RT [MART]), two hyperfractionated schemes (using an identical (HRTI) or higher (HRTH) total treatment dose than CRT) and CRT. Results: All modified fractionations were more effective and costlier than CRT (1.12 QALYs, €24,360). VART and MART were most effective (1.30 and 1.32 QALYs) and cost €25,746 and €26,208, respectively. HRTI and HRTH yielded less QALYs than the accelerated schemes (1.27 and 1.14 QALYs), and cost €26,199 and €29,683, respectively. MART had the highest NMB (€79,322; 95% confidence interval [CI], €35,478-€133,648) and was the most cost-effective treatment followed by VART (€78,347; 95% CI, €64,635-€92,526). CRT had an NMB of €65,125 (95% CI, €54,663-€75,537). MART had the highest probability of being cost effective (43%), followed by VART (31%), HRTI (24%), HRTH (2%), and CRT (0%). Conclusion: Implementing accelerated RT is almost certainly more efficient than current practice CRT and should be recommended as standard RT for the curative treatment of unresected NSCLC patients not receiving concurrent chemo-radiotherapy. Copyright © 2013 by the International Association for the Study of Lung Cancer.

Published
2013

24. Multicenter phase II study of cetuximab (C) with concomitant radiotherapy (RT) followed by consolidation chemotherapy (CT) in locally advanced non-small cell lung cancer (NSCLC).

Author

Kotsakis, A. P., primary, Ramalingam, S. S., additional, Tarhini, A. A., additional, Heron, D. E., additional, Smith, R., additional, Friedland, D., additional, Petro, D. P., additional, Raez, L. E., additional, Brahmer, J. R., additional, Greenberger, J. S., additional, Dacic, S., additional, Hershberger, P., additional, Landreneau, R. J., additional, Belani, C. P., additional, Luketich, J. D., additional, and Argiris, A., additional

Published
2011
Full Text
View/download PDF

29. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC).

Author

Belani, C. P., primary, Waterhouse, D. M., additional, Ghazal, H., additional, Ramalingam, S. S., additional, Bordoni, R., additional, Greenberg, R., additional, Levine, R. M., additional, Waples, J. M., additional, Jiang, Y., additional, and Reznikoff, G., additional

Published
2010
Full Text
View/download PDF

33. A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase (MnSOD) plasmid liposome (PL) protection in patients with locally advanced stage III non-small cell lung cancer.

Author

Schillo, R. E., primary, Tarhini, A. A., additional, Belani, C. P., additional, Luketich, J. D., additional, Argiris, A., additional, Ramalingam, S. S., additional, Liggitt, D., additional, Championsmith, T., additional, Epperly, M. W., additional, and Greenberger, J. S., additional

Published
2010
Full Text
View/download PDF

36. 9007 Randomized, double-blind phase II/III study of first-line paclitaxel (P) plus carboplatin (C) in combination with vorinostat or placebo in patients with advanced non-small-cell lung cancer (NSCLC)

Author

Belani, C., primary, Ramalingam, S., additional, Kalemkerian, G., additional, Mok, T., additional, Rosell, R., additional, Ahn, M.J., additional, Sun, L., additional, Gates, M., additional, Lubiniecki, G.M., additional, and Govindan, R., additional

Published
2009
Full Text
View/download PDF

38. Incidence and outcomes associated with brain metastases (BM) in a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC)

Author

Edelman, M. J., primary, Belani, C. P., additional, Socinski, M. A., additional, Ansari, R., additional, Obasaju, C. K., additional, Monberg, M. J., additional, Chen, R., additional, and Treat, J., additional

Published
2009
Full Text
View/download PDF

40. A phase II study of the halichondrin B analog, E7389, in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a taxane. A California Consortium/University of Pittsburgh/University of Chicago NCI/CTEP sponsored trial

Author

Gitlitz, B. J., primary, Davies, A. M., additional, Belani, C. P., additional, Argiris, A., additional, Ramalingam, S. S., additional, Hoffman, P. C., additional, Koczwas, M., additional, Groshen, S. G., additional, and Gandara, D. R., additional

Published
2009
Full Text
View/download PDF

42. Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863)

Author

Ramalingam, S. S., primary, Maitland, M., additional, Frankel, P., additional, Argiris, A. E., additional, Koczywas, M., additional, Gitlitz, B., additional, Espinoza-Delgado, I., additional, Vokes, E. E., additional, Gandara, D. R., additional, and Belani, C. P., additional

Published
2009
Full Text
View/download PDF

49. Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study

Author

Ramalingam, S. S., primary, Dahlberg, S. E., additional, Langer, C. J., additional, Gray, R., additional, Belani, C. P., additional, Brahmer, J. R., additional, Sandler, A., additional, Schiller, J. H., additional, and Johnson, D. H., additional

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results